Virtus ETF Advisers LLC Rapt Therapeutics, Inc. Transaction History

Virtus ETF Advisers LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$6.87 - $26.45 $2,115 - $8,146	-308 Reduced 6.43%	4,479 $40,000
Q4 2023 Feb 15, 2024	BUY	$11.28 - $25.46 $1,082 - $2,444	96 Added 2.05%	4,787 $118,000
Q3 2023 Nov 07, 2023	SELL	$16.34 - $24.66 $7,549 - $11,392	-462 Reduced 8.97%	4,691 $77,000
Q2 2023 Aug 14, 2023	SELL	$16.06 - $21.61 $5,621 - $7,563	-350 Reduced 6.36%	5,153 $96,000
Q1 2023 May 15, 2023	SELL	$17.19 - $30.8 $36,477 - $65,357	-2,122 Reduced 27.83%	5,503 $100,000
Q4 2022 Feb 14, 2023	BUY	$16.28 - $24.6 $9,930 - $15,006	610 Added 8.7%	7,625 $150,000
Q3 2022 Nov 14, 2022	BUY	$17.96 - $30.46 $915 - $1,553	51 Added 0.73%	7,015 $169,000
Q2 2022 Aug 12, 2022	BUY	$10.26 - $23.59 $19,309 - $44,396	1,882 Added 37.03%	6,964 $127,000
Q1 2022 May 16, 2022	SELL	$17.02 - $40.22 $5,225 - $12,347	-307 Reduced 5.7%	5,082 $112,000
Q4 2021 Feb 14, 2022	BUY	$29.5 - $39.5 $2,271 - $3,041	77 Added 1.45%	5,389 $198,000
Q3 2021 Nov 15, 2021	SELL	$29.86 - $39.47 $8,271 - $10,933	-277 Reduced 4.96%	5,312 $165,000
Q2 2021 Aug 10, 2021	SELL	$17.99 - $40.02 $122,188 - $271,815	-6,792 Reduced 54.86%	5,589 $178,000
Q1 2021 May 17, 2021	BUY	$16.0 - $24.46 $3,616 - $5,527	226 Added 1.86%	12,381 $275,000
Q4 2020 Feb 12, 2021	SELL	$15.89 - $40.87 $34,354 - $88,360	-2,162 Reduced 15.1%	12,155 $240,000
Q3 2020 Nov 13, 2020	SELL	$21.6 - $37.5 $42,271 - $73,387	-1,957 Reduced 12.03%	14,317 $461,000
Q2 2020 Aug 05, 2020	BUY	$14.16 - $32.85 $230,439 - $534,600	16,274 New	16,274 $472,000

104

27.1M

26.7K

2.4K

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $26.1M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.